Search - tctmd.com

Displaying 321 - 340 of 2106

Sort: Relevancy | Date

News Daily News

Poor Sleep Quality Linked to CVD Events and Mortality

Yael L. Maxwell

April 25, 2024

News Daily News

Pregnancy Complications Impart Higher Death Risk for Decades

Caitlin E. Cox

April 24, 2024

News Daily News

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Michael O'Riordan

April 17, 2024

News Daily News

Tirzepatide Eases Obstructive Sleep Apnea in Patients With Obesity

Todd Neale

April 17, 2024

News Conference News ACC 2024

HUDDLE Up! High BP and Cardiac Changes Prevalent in Retired NFL Players

Michael O'Riordan

April 15, 2024

News Conference News ACC 2024

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Michael O'Riordan

April 12, 2024

News Conference News ACC 2024

KARDIA-2: Zilebesiran Drops BP on Top of Common Antihypertensives

Shelley Wood

April 11, 2024

News Conference News ACC 2024

BE ACTIVE: Gaming for Points and Money Can Boost Step Counts

L.A. McKeown

April 11, 2024

News Conference News ACC 2024

Need a Statin for Primary Prevention? There’s an App for That

Michael O'Riordan

April 10, 2024

News Conference News ACC 2024

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

Yael L. Maxwell

April 09, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

Presentation ACC 2024

Randomized, Double-blind, Placebo-controlled, Phase 3, Study To Evaluate Lerodalcibep Long-term Efficacy And Safety In Patients With, Or At Very-high Or High Risk, For Cardiovascular Disease On Stable Lipid-lowering Therapy

Presenter: Eric Quinton Klug

April 07, 2024

News Conference News ACC 2024

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

L.A. McKeown

April 06, 2024

Presentation ACC 2024

Comparison of an “Inclisiran First” Strategy With Usual Care in Patients With Atherosclerotic Cardiovascular Disease: Results From the VICTORION-INITIATE Randomized Trial

Presenter: Michael J. Koren

April 06, 2024

News Conference News ACC 2024

Faster CAC Progression After Menopause May Warrant Intensified Therapy

L.A. McKeown

April 04, 2024

News Opinion CV Team Dispatch

April 2024 Dispatch for the CV Team

L.A. McKeown

April 01, 2024

News Conference News ACC 2024

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

Todd Neale

March 27, 2024

News Conference News

Lifestyle Changes Can Curb CVD Risk After Adverse Pregnancy Outcomes

Yael L. Maxwell

March 26, 2024

News Daily News

Bempedoic Acid Gains CV Risk Reduction Indication

Todd Neale

March 22, 2024

News Conference News

Intermittent Fasting Study Sparks Debate Over Increases in CV Mortality

Michael O'Riordan

March 22, 2024

Advertisement

Poor Sleep Quality Linked to CVD Events and Mortality

Pregnancy Complications Impart Higher Death Risk for Decades

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Tirzepatide Eases Obstructive Sleep Apnea in Patients With Obesity

HUDDLE Up! High BP and Cardiac Changes Prevalent in Retired NFL Players

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

KARDIA-2: Zilebesiran Drops BP on Top of Common Antihypertensives

BE ACTIVE: Gaming for Points and Money Can Boost Step Counts

Need a Statin for Primary Prevention? There’s an App for That

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Randomized, Double-blind, Placebo-controlled, Phase 3, Study To Evaluate Lerodalcibep Long-term Efficacy And Safety In Patients With, Or At Very-high Or High Risk, For Cardiovascular Disease On Stable Lipid-lowering Therapy

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

Comparison of an “Inclisiran First” Strategy With Usual Care in Patients With Atherosclerotic Cardiovascular Disease: Results From the VICTORION-INITIATE Randomized Trial

Faster CAC Progression After Menopause May Warrant Intensified Therapy

April 2024 Dispatch for the CV Team

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

Lifestyle Changes Can Curb CVD Risk After Adverse Pregnancy Outcomes

Bempedoic Acid Gains CV Risk Reduction Indication

Intermittent Fasting Study Sparks Debate Over Increases in CV Mortality

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content